|Pluristem Advances Its Second Major Cell Therapy Product Line From ...|
... today that it has completed development of its second major product line, and can now begin manufacturing the cells on a large-scale at its state-of-the art facility in order to meet demand for anticipated studies in a range of hematologic conditions.
MarketWatch - Tue, 21 Oct 2014 00:03
|Adaptive Biotechnologies Announces the Formation of a Hematologic ...|
Adaptive plans to work closely with the SAB to generate additional clinical evidence for the utility of clonoSEQ to measure relapse in patients with diseases such as Multiple Myeloma and Lymphoma, where MRD has traditionally been more difficult to ...
SYS-CON Media (press release) - Mon, 29 Sep 2014 08:47
|The Leukemia & Lymphoma Society Announces Recipients of Grants Supporting ...|
Epstein bar virus (EBV) is a common cause of several lymphomas and there are currently no therapies directed against EBV for these diseases. EBNA1 is a protein that prevents infectious B-cells from dying and appears to play a role ... Ruben Carrasco, M ...
SYS-CON Media (press release) - Tue, 21 Oct 2014 09:04
|Fast Track Designation Granted to TAS-102 in mCRC|
"Patients with metastatic colorectal cancer, whose disease has progressed after treatment with standard therapies, have limited treatment options to manage their disease. We have initiated our rolling ... with a very mild safety profile. The most ...
OncLive - Mon, 20 Oct 2014 13:48
|Protecting Bone and Arterial Health with Vitamin k2|
In fact, low levels of vitamin K2 are associated with an increased risk of heart disease and atherosclerosis.1 Astute doctors have long known that people with a lack of calcium in their bones are more likely to possess an excess of calcium in their ...
ProHealth - Tue, 21 Oct 2014 17:00
|Impact of rabbit ATG-containing myeloablative conditioning regimens on the ...|
Allogeneic hematopoietic SCT (allo-SCT) is a curative therapeutic approach in a wide variety of otherwise incurable hematological disorders.1 Unrelated umbilical cord blood transplantation (UCBT) has emerged as a valid alternative source of stem cells ...
Nature.com - Mon, 20 Oct 2014 07:55
|Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613 for ...|
CRANBURY, N.J., Oct. 21, 2014 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a Phase I clinical trial of CPI-613 ...
GlobeNewswire (press release) - Tue, 21 Oct 2014 09:07
|Oral Therapies Shift Treatment Paradigm in CLL|
In September 2014, the manufacturer of duvelisib, Infinity, announced a series of collaborations to explore the drug as a treatment for patients with hematologic malignancies. ... Altogether, 22% were deemed minimal residual disease (MRD)-negative.
OncLive - Mon, 20 Oct 2014 10:15